Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AZD0305 alone or with anticancer agents in multiple myeloma
CTR20241689Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AZD0305 in multiple myeloma (MM) (2 arms), sponsored by AstraZeneca. Started Aug 2024; status: active.
02
Drugs
AZD0305
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20241689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241689.